BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 35544087)

  • 1. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
    Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
    Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
    Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
    Front Immunol; 2022; 13():832501. PubMed ID: 35281023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients.
    Sakuraba A; Luna A; Micic D
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-spike antibody durability after SARS-CoV-2 vaccination in adolescent solid organ transplant recipients.
    McAteer J; Kalluri DD; Abedon RR; Qin CX; Auerbach SR; Charnaya O; Danziger-Isakov LA; Ebel NH; Feldman AG; Hsu EK; Mohammad S; Perito ER; Thomas AM; Chiang TPY; Garonzik-Wang JM; Segev DL; Werbel WA; Mogul DB
    Pediatr Transplant; 2024 Feb; 28(1):e14671. PubMed ID: 38317335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination.
    Chiang TP; Alejo JL; Mitchell J; Kim JD; Abedon AT; Karaba AH; Thomas L; Levan ML; Garonzik-Wang JM; Avery RK; Pekosz A; Clarke WA; Warren DS; Tobian AAR; Massie AB; Segev DL; Werbel WA
    Am J Transplant; 2022 Sep; 22(9):2254-2260. PubMed ID: 35429211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of mRNA Vaccine Immunogenicity in Solid Organ Transplant Recipients.
    Tsoutsoura P; Xagas E; Roussos S; Hatzakis A; Gourzi P; Boletis IN; Marinaki S
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374279
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis.
    Manothummetha K; Chuleerarux N; Sanguankeo A; Kates OS; Hirankarn N; Thongkam A; Dioverti-Prono MV; Torvorapanit P; Langsiri N; Worasilchai N; Moonla C; Plongla R; Garneau WM; Chindamporn A; Nissaisorakarn P; Thaniyavarn T; Nematollahi S; Permpalung N
    JAMA Netw Open; 2022 Apr; 5(4):e226822. PubMed ID: 35412626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of BNT162b2 and mRNA1273 vaccines in solid organ transplant recipients: Post-Hoc analysis of a Japanese national prospective study.
    Yoshikawa M; Natori Y; Oki R; Unagami K; Ohfuji S; Imamura R; Ishida H; Takahara S; Hirota Y; Egawa H
    Scand J Immunol; 2023 Oct; 98(4):e13308. PubMed ID: 38441221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients.
    Natori Y; Martin E; Mattiazzi A; Arosemena L; Ortigosa-Goggins M; Shobana S; Roth D; Kupin WL; Burke GW; Ciancio G; Morsi M; Phancao A; Munagala MR; Butrous H; Manickavel S; Sinha N; Sota K; Pallikkuth S; Bini J; Simkins J; Anjan S; Vianna RM; Guerra G
    Transpl Int; 2023; 36():10938. PubMed ID: 37091963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients: The CONTRAST Cohort.
    Bonazzetti C; Tazza B; Gibertoni D; Pasquini Z; Caroccia N; Fanì F; Fornaro G; Pascale R; Rinaldi M; Miani B; Gamberini C; Morelli MC; Tamé M; Busutti M; Comai G; Potena L; Borgese L; Salvaterra E; Lazzarotto T; Scudeller L; Viale P; Giannella M;
    Clin Infect Dis; 2023 May; 76(10):1761-1767. PubMed ID: 36636955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls.
    Yanis A; Haddadin Z; Spieker AJ; Waqfi D; Rankin DA; Talj R; Thomas L; Birdwell KA; Ezzell L; Blair M; Eason J; Varjabedian R; Warren CM; Nochowicz CH; Olson EC; Simmons JD; Yoder S; Guy M; Thomsen I; Chappell JD; Kalams SA; Halasa NB
    Transpl Infect Dis; 2022 Feb; 24(1):e13772. PubMed ID: 34905653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial.
    Speich B; Chammartin F; Abela IA; Amico P; Stoeckle MP; Eichenberger AL; Hasse B; Braun DL; Schuurmans MM; Müller TF; Tamm M; Audigé A; Mueller NJ; Rauch A; Günthard HF; Koller MT; Trkola A; Briel M; Kusejko K; Bucher HC;
    Clin Infect Dis; 2022 Aug; 75(1):e585-e593. PubMed ID: 35234868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
    Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
    BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
    Davidov Y; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Levy I; Levin EG; Lustig Y; Mor O; Rahav G; Ben Ari Z
    Liver Transpl; 2022 Feb; 28(2):215-223. PubMed ID: 34767690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
    Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
    Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
    Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
    JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
    Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
    Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
    Mazzola A; Todesco E; Drouin S; Hazan F; Marot S; Thabut D; Varnous S; Soulié C; Barrou B; Marcelin AG; Conti F
    Clin Infect Dis; 2022 Mar; 74(6):1093-1096. PubMed ID: 34166499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).
    Haidar G; Agha M; Bilderback A; Lukanski A; Linstrum K; Troyan R; Rothenberger S; McMahon DK; Crandall MD; Sobolewksi MD; Nathan Enick P; Jacobs JL; Collins K; Klamar-Blain C; Macatangay BJC; Parikh UM; Heaps A; Coughenour L; Schwartz MB; Dueker JM; Silveira FP; Keebler ME; Humar A; Luketich JD; Morrell MR; Pilewski JM; McDyer JF; Pappu B; Ferris RL; Marks SM; Mahon J; Mulvey K; Hariharan S; Updike GM; Brock L; Edwards R; Beigi RH; Kip PL; Wells A; Minnier T; Angus DC; Mellors JW
    Clin Infect Dis; 2022 Aug; 75(1):e630-e644. PubMed ID: 35179197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.